• Gain Therapeutics’ third-quarter 2026 net loss narrowed 40% year over year to $3.16 million.
• Research and development expenses fell 50% year over year to $1.42 million.
• Cash and cash equivalents dropped 44% from December 31, 2025, to $11.7 million at September 30, 2026.
• Rexaceract’s Phase 1b extension showed no motor-symptom progression among 12 evaluable Parkinson’s participants through 12 months of dosing.
• A Phase 2 trial of rexaceract in Parkinson’s disease is expected to begin in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gain Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100700PRIMZONEFULLFEED9874085) on November 10, 2026, and is solely responsible for the information contained therein.